HK Stock Market Move | PONY-W(02026) opened high by nearly 6% and reached a strategic cooperation agreement with Moore Thread, jointly promoting the adaptation and verification of world and vehicle end model training.
Xiao Ma Intelligent Travel Group (02026) opened nearly 6% higher, as of the time of publication, it was up 5.88% to 109.8 Hong Kong dollars, with a turnover of 156.88 million Hong Kong dollars.
PONY-W (02026) opened nearly 6% higher, rising 5.88% to HK$109.8 as of press time, with a trading volume of HK$156.488 million.
On the news front, on February 6th, PONY-W officially announced a strategic partnership with Moore Threads (688795.SH). The two parties will focus on the implementation and scale application of L4 level autonomous driving technology, and will deepen their cooperation around PONY-W's technological core - the world model and virtual driver system training and optimization. With safe and reliable AI computing power, they aim to empower the iteration and commercial application of autonomous driving technology. This collaboration is an important demonstration of collaborative innovation in the Chinese artificial intelligence industry chain - PONY-W is using domestically-produced AI computing power on a large scale for the first time in key training and simulation processes, marking the entry of Moore Threads' domestically-produced full-function GPU into the core area of autonomous driving.
It is reported that the two parties will jointly promote the training adaptation and verification of PONY-W's world model and vehicle-side model based on Moore Threads' MTT S5000 Train & Push Integrated Intelligence Card and Kingfisher Intelligence Computing Cluster. By jointly building an autonomous driving computing power ecosystem, they aim to achieve full-chain collaboration of "algorithm-data-computing power-application", accelerate the maturity and cost optimization of L4 level autonomous driving technology, and provide solid support for the high-quality development of intelligent travel and logistics industry.
Related Articles

HK Stock Market Move | SINO BIOPHARM (01177) rose more than 3% with the completion of subject enrollment in Phase III clinical trial of Vituximab Bevacizumab "CLDN18.2 ADC".

HK Stock Market Move | JIAXIN INTL RES (03858) surges more than 6%, expected to turn loss into profit last year, with a maximum profit of up to HK$340 million.

BofA Securities: Maintains "Buy" rating on INNOVENT BIO (01801) with a target price of HK$113.5.
HK Stock Market Move | SINO BIOPHARM (01177) rose more than 3% with the completion of subject enrollment in Phase III clinical trial of Vituximab Bevacizumab "CLDN18.2 ADC".

HK Stock Market Move | JIAXIN INTL RES (03858) surges more than 6%, expected to turn loss into profit last year, with a maximum profit of up to HK$340 million.

BofA Securities: Maintains "Buy" rating on INNOVENT BIO (01801) with a target price of HK$113.5.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


